Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-25 @ 7:21 PM
Study NCT ID:
NCT04996004
Status:
TERMINATED
Last Update Posted:
2024-12-11
First Post:
2021-08-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007890', 'term': 'Leiomyosarcoma'}, {'id': 'D018223', 'term': 'Dermatofibrosarcoma'}, {'id': 'D008080', 'term': 'Liposarcoma'}, {'id': 'D006394', 'term': 'Hemangiosarcoma'}, {'id': 'D012509', 'term': 'Sarcoma'}], 'ancestors': [{'id': 'D009379', 'term': 'Neoplasms, Muscle Tissue'}, {'id': 'D018204', 'term': 'Neoplasms, Connective and Soft Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005354', 'term': 'Fibrosarcoma'}, {'id': 'D018218', 'term': 'Neoplasms, Fibrous Tissue'}, {'id': 'D009372', 'term': 'Neoplasms, Connective Tissue'}, {'id': 'D018205', 'term': 'Neoplasms, Adipose Tissue'}, {'id': 'D009383', 'term': 'Neoplasms, Vascular Tissue'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000626237', 'term': 'TTI-621'}, {'id': 'D004317', 'term': 'Doxorubicin'}], 'ancestors': [{'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From first dose of study treatment (Day 1up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurs soonest (maximum exposure up to 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively)', 'description': 'Same event may appear as both AE and SAE, what is presented are distinct events. An event may be categorized as serious in 1 participant and non-serious in another participant, or a participant may have experienced both SAE and non-SAE. SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.', 'eventGroups': [{'id': 'EG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 1, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 2, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 1, 'seriousNumAffected': 1}, {'id': 'EG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 24, 'seriousNumAtRisk': 32, 'deathsNumAffected': 12, 'seriousNumAffected': 9}, {'id': 'EG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 12, 'seriousNumAtRisk': 13, 'deathsNumAffected': 2, 'seriousNumAffected': 8}, {'id': 'EG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.', 'otherNumAtRisk': 22, 'deathsNumAtRisk': 22, 'otherNumAffected': 21, 'seriousNumAtRisk': 22, 'deathsNumAffected': 9, 'seriousNumAffected': 15}], 'otherEvents': [{'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 20}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 14}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 11}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 22}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 15}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 14}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 16}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 11}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 19}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 15}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 10}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Blood alkaline phosphatase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Blood lactate dehydrogenase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 6}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 5}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Infusion related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 14}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 11}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Rhinitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Flank pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Groin pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 12}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Vision blurred', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Sinus tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}], 'seriousEvents': [{'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Endocarditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pelvic abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Staphylococcal bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Staphylococcal sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Small intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Enterocolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Haemorrhoidal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Lower gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Cerebrovascular accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Aphasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Spinal cord compression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Cardiac hypertrophy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Cardiotoxicity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Mitral valve disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Myocardial fibrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Myocardial ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pneumonitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Infusion related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Failure to thrive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Bone pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Neoplasm progression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Axillary vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Subclavian vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}, {'term': 'Vaginal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 22, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Participants with TEAEs', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Participants with Serious TEAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition following or during exposure to pharmaceutical product, whether or not considered causally related to product. A serious adverse event (SAE) was an adverse event occurred during any study at any dose of the investigational products that fulfils one or more of following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. TEAEs were those events with onset date occurred during on-treatment period. AEs included SAEs and all Non-SAEs. On-treatment period was defined as time from first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer therapy). Participant with at least one TEAE and one serious TEAEs are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set (SAS) included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 1 (C1D1): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '-0.7', 'spread': '5.86', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '3.51', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '8.72', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '1.7', 'spread': '8.02', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '3.61', 'groupId': 'OG001'}, {'value': '-8.7', 'spread': '4.73', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 1', 'description': 'Blood pressure included diastolic blood pressure (DBP) and systolic blood pressure (SBP). Mean change from baseline to 30 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury (mmHg)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D1: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '2.3', 'spread': '2.08', 'groupId': 'OG000'}, {'value': '0.7', 'spread': '3.21', 'groupId': 'OG001'}, {'value': '1.7', 'spread': '9.29', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '3.0', 'spread': '5.00', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '2.89', 'groupId': 'OG001'}, {'value': '-8.3', 'spread': '10.12', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 8 (C1D8): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '1.3', 'spread': '10.02', 'groupId': 'OG000'}, {'value': '2.7', 'spread': '5.03', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '2.89', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '7.0', 'spread': '11.36', 'groupId': 'OG000'}, {'value': '5.0', 'spread': '6.93', 'groupId': 'OG001'}, {'value': '-7.3', 'spread': '7.51', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 30 minutes post dose on Day 8 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D8: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I : Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '0.3', 'spread': '9.81', 'groupId': 'OG000'}, {'value': '-4.0', 'spread': '7.94', 'groupId': 'OG001'}, {'value': '0.7', 'spread': '6.51', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '3.3', 'spread': '9.07', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '9.29', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '11.53', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 60 minutes post dose on Day 8 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 2 Day 1 (C2D1): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '3.0', 'spread': '3.46', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '6.24', 'groupId': 'OG001'}, {'value': '6.5', 'spread': '3.54', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '4.0', 'spread': '5.29', 'groupId': 'OG000'}, {'value': '-5.7', 'spread': '6.51', 'groupId': 'OG001'}, {'value': '3.5', 'spread': '16.26', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 2', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C2D1: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '3.0', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '-3.7', 'spread': '8.02', 'groupId': 'OG001'}, {'value': '11.0', 'spread': '1.41', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '5.0', 'spread': '5.57', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '14.73', 'groupId': 'OG001'}, {'value': '10.5', 'spread': '24.75', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 2', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 3 Day 1 (C3D1): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '-3.5', 'spread': '6.36', 'groupId': 'OG000'}, {'value': '-5.5', 'spread': '4.95', 'groupId': 'OG001'}, {'value': '2.0', 'spread': 'NA', 'comment': 'Standard deviation (SD) could not be calculated as only 1 participant was analyzed.', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '-6.5', 'spread': '17.68', 'groupId': 'OG000'}, {'value': '-14.0', 'spread': '0.00', 'groupId': 'OG001'}, {'value': '-8.0', 'spread': 'NA', 'comment': 'SD could not be calculated as only 1 participant was analyzed.', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 3', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C3D1: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '0.5', 'spread': '6.36', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '2.83', 'groupId': 'OG001'}, {'value': '6.0', 'spread': 'NA', 'comment': 'SD could not be calculated as only 1 participant was analyzed.', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '-1.0', 'spread': '7.07', 'groupId': 'OG000'}, {'value': '-12.0', 'spread': '4.24', 'groupId': 'OG001'}, {'value': '-11.0', 'spread': 'NA', 'comment': 'SD could not be calculated as only 1 participant was analyzed.', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 3', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Blood Pressure at Safety Follow up: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP', 'categories': [{'measurements': [{'value': '7.0', 'spread': '2.83', 'groupId': 'OG000'}, {'value': '-10.3', 'spread': '2.89', 'groupId': 'OG001'}, {'value': '3.0', 'spread': '13.08', 'groupId': 'OG002'}]}]}, {'title': 'SBP', 'categories': [{'measurements': [{'value': '13.5', 'spread': '14.85', 'groupId': 'OG000'}, {'value': '-15.7', 'spread': '10.07', 'groupId': 'OG001'}, {'value': '8.7', 'spread': '12.66', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to safety follow up visit were reported in this outcome measure. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Body Weight at C3D1: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.68', 'spread': '0.962', 'groupId': 'OG000'}, {'value': '-3.86', 'spread': '2.885', 'groupId': 'OG001'}, {'value': '-1.71', 'spread': '0.148', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 of Cycle 3', 'description': 'Body weight was measured in kilograms (kg). Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Body Weight at Cycle 5 Day 1 (C5D1): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.91', 'spread': '0.000', 'groupId': 'OG000'}, {'value': '-2.50', 'spread': '5.452', 'groupId': 'OG001'}, {'value': '-2.09', 'spread': '1.534', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 of Cycle 5', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Body Weight at Cycle 7 Day 1 (C7D1): Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.91', 'spread': '0.636', 'groupId': 'OG000'}, {'value': '-0.23', 'spread': '2.249', 'groupId': 'OG001'}, {'value': '-1.26', 'spread': '0.785', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 of Cycle 7', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Mean Change From Baseline in Body Weight at Safety Follow up: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.13', 'spread': '0.325', 'groupId': 'OG000'}, {'value': '-3.48', 'spread': '1.889', 'groupId': 'OG001'}, {'value': '-1.56', 'spread': '1.794', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Overall Electrocardiogram (ECG) Abnormalities: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': "Standard 12- lead ECGs, average of triplicate assessments were obtained in participant in supine position and within 10 minutes total time. ECG abnormalities included: PR interval (millisecond \\[msec\\]): value greater than or equal to (\\>=) 220 and change from baseline \\>=20; QRS interval (msec) value \\>=120; uncorrected QT interval, QT correct by Bazzette's formula (QTcB) interval and QT correct by Frederica formula (QTcF) interval (msec): value greater than (\\>) 450, value \\> 480, value \\> 500, change from baseline \\> 30 and \\> 60. Baseline was defined as the last assessment prior to the date or time of the first dose of study treatment. In this outcome measure number of participants with overall ECG abnormalities are reported.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Shift in National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v)5.0 Grade <=2 at Baseline to >=3 Post-baseline in Hematology Parameters: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Shift from baseline Grade to post-baseline Grade 3: Leukocytes (10^9/L) white blood cells decreased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: Leukocytes (10^9/L) white blood cells decreased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Neutrophils (10^9/L) decreased', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: Neutrophils (10^9/L) decreased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Platelets (10^9/L) decreased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'The following hematology laboratory parameters were assessed: hemoglobin, hematocrit, platelets, white blood cells (WBC), neutrophils, lymphocytes, eosinophils, basophils, monocytes, WBC with automated 5-part differential, Red blood cells (RBC), absolute reticulocytes, reticulocytes percentage (%), Mean corpuscular hemoglobin (MCH), Mean corpuscular volume (MCV) and Red cell distribution width (RDW). Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Baseline was defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants who had hematology parameter abnormality Grade \\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Chemistry Parameters: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Shift from baseline Grade to post-baseline Grade 3: ALT (U/L) increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: AST (U/L) increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'The following chemistry parameters were assessed: glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate, blood urea nitrogen or urea, creatinine, total protein, albumin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, indirect bilirubin, uric acid, calcium, magnesium, lactate dehydrogenase (LDH). Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death related to adverse event. Baseline was defined as last assessment prior to date/time of first dose of study treatment. Number of participants who had chemistry parameter abnormality Grade\\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Dose Modifications: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Participants with dose reduction- Ontorpacept', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose omitted- Ontorpacept', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Participants with infusion interruption-Ontorpacept', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Participants with cycle delayed- Ontorpacept', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose reduction- Doxorubicin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose omitted- Doxorubicin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with infusion interruption-Doxorubicin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with cycle delayed- Doxorubicin', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 74.1 weeks for ontorpacept and 20.1 weeks for doxorubicin)', 'description': 'Dose modifications included dose reduction, dose omitted, infusion interruption and cycle delayed.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment Discontinuations: Phase I', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Ontorpacept', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Doxorubicin', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 74.1 weeks for ontorpacept and 20.1 weeks for doxorubicin)', 'description': 'Number of participants with treatment discontinuations during the study treatment were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'PRIMARY', 'title': 'Objective Response Rate (ORR): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '70.8'}, {'value': '0.0', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '70.8'}, {'value': '33.3', 'groupId': 'OG002', 'lowerLimit': '0.8', 'upperLimit': '90.6'}, {'value': '18.8', 'groupId': 'OG003', 'lowerLimit': '7.2', 'upperLimit': '36.4'}, {'value': '0.0', 'groupId': 'OG004', 'lowerLimit': '0.0', 'upperLimit': '24.7'}, {'value': '4.5', 'groupId': 'OG005', 'lowerLimit': '0.1', 'upperLimit': '22.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the start of study treatment until disease progression (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': "ORR: percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) based on investigator's assessment per response evaluation criteria in solid tumours RECIST version (v)1.1. BOR: best response recorded from start of treatment until disease progression (PD). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than(\\< )10 mm. PR: at least 30 percent (%) decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. PD: at least 20% increase in sum of longest diameter of target lesions, taking as reference of the smallest sum on study.", 'unitOfMeasure': 'Percentage of Participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With TEAEs and Serious TEAEs: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Participants with TEAEs', 'categories': [{'measurements': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}]}, {'title': 'Participants with Serious TEAEs', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'An AE was any untoward medical occurrence or worsening of a pre-existing medical condition following or during exposure to pharmaceutical product, whether or not considered causally related to product. A SAE was an adverse event occurred during any study at any dose of the investigational products that fulfils one or more of following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. TEAEs were those events with onset date occurred during on-treatment period. AEs included SAEs and all Non-SAEs. On-treatment period was defined as time from first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer therapy). Participant with at least one TEAE and one serious TEAEs are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Blood Pressure: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'DBP: Change at 30 minutes post dose on C1D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '7.46', 'groupId': 'OG000'}, {'value': '-8.8', 'spread': '5.37', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '11.31', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 60 minutes post dose on C1D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '6.73', 'groupId': 'OG000'}, {'value': '-7.8', 'spread': '7.01', 'groupId': 'OG001'}, {'value': '-4.5', 'spread': '11.88', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 30 minutes post dose on C1D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-10.0', 'spread': '12.82', 'groupId': 'OG000'}, {'value': '-15.4', 'spread': '15.06', 'groupId': 'OG001'}, {'value': '-3.6', 'spread': '14.04', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 60 minutes post dose on C1D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'spread': '12.18', 'groupId': 'OG000'}, {'value': '-18.3', 'spread': '15.70', 'groupId': 'OG001'}, {'value': '-6.5', 'spread': '14.79', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 30 minutes post dose on C1D8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '10.78', 'groupId': 'OG000'}, {'value': '-5.0', 'spread': '6.63', 'groupId': 'OG001'}, {'value': '6.3', 'spread': '15.26', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 60 minutes post dose on C1D8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '9.08', 'groupId': 'OG000'}, {'value': '-4.8', 'spread': '5.81', 'groupId': 'OG001'}, {'value': '1.7', 'spread': '2.52', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 30 minutes post dose on C1D8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-9.0', 'spread': '14.23', 'groupId': 'OG000'}, {'value': '-7.0', 'spread': '16.52', 'groupId': 'OG001'}, {'value': '15.5', 'spread': '20.14', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 60 minutes post dose on C1D8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.8', 'spread': '12.26', 'groupId': 'OG000'}, {'value': '-9.5', 'spread': '14.54', 'groupId': 'OG001'}, {'value': '11.7', 'spread': '8.96', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 30 minutes post dose on C2D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '6.58', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '8.30', 'groupId': 'OG001'}, {'value': '-7.6', 'spread': '15.95', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 60 minutes post dose on C2D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '7.27', 'groupId': 'OG000'}, {'value': '-3.5', 'spread': '8.23', 'groupId': 'OG001'}, {'value': '-3.1', 'spread': '13.36', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 30 minutes post dose on C2D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-9.1', 'spread': '14.57', 'groupId': 'OG000'}, {'value': '-3.3', 'spread': '19.29', 'groupId': 'OG001'}, {'value': '-9.9', 'spread': '17.51', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 60 minutes post dose on C2D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.7', 'spread': '11.62', 'groupId': 'OG000'}, {'value': '-11.5', 'spread': '5.80', 'groupId': 'OG001'}, {'value': '-6.3', 'spread': '13.41', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 30 minutes post dose on C3D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.4', 'spread': '4.09', 'groupId': 'OG000'}, {'value': '-6.8', 'spread': '13.02', 'groupId': 'OG001'}, {'value': '-2.3', 'spread': '6.50', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at 60 minutes post dose on C3D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '6.16', 'groupId': 'OG000'}, {'value': '-10.0', 'spread': '9.90', 'groupId': 'OG001'}, {'value': '-2.0', 'spread': '1.00', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 30 minutes post dose on C3D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-14.1', 'spread': '12.20', 'groupId': 'OG000'}, {'value': '-7.3', 'spread': '10.66', 'groupId': 'OG001'}, {'value': '-7.3', 'spread': '20.50', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at 60 minutes post dose on C3D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-14.3', 'spread': '13.37', 'groupId': 'OG000'}, {'value': '-11.8', 'spread': '5.74', 'groupId': 'OG001'}, {'value': '-8.0', 'spread': '17.44', 'groupId': 'OG002'}]}]}, {'title': 'DBP: Change at safety follow up', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '12.10', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '13.52', 'groupId': 'OG001'}, {'value': '2.1', 'spread': '12.95', 'groupId': 'OG002'}]}]}, {'title': 'SBP: Change at safety follow up', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.9', 'spread': '16.86', 'groupId': 'OG000'}, {'value': '-2.4', 'spread': '26.30', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '16.11', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, 30 and 60min post dose of C1D1,C1D8,C2D1,C3D1 and safety follow up 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure of Phase II:88 weeks;maximum follow up:92 weeks)', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to safety follow up visit were reported in this outcome measure. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).', 'unitOfMeasure': 'Millimeter of mercury', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. All participants reported under "Number of Participants Analyzed" contributed data to the table; however, may not have evaluable data for every row. Here, "Number Analyzed" signifies number of participants evaluable at specified time points.'}, {'type': 'SECONDARY', 'title': 'Mean Change From Baseline in Body Weight: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Change at C3D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '25', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.30', 'spread': '1.765', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '2.122', 'groupId': 'OG001'}, {'value': '-1.83', 'spread': '1.637', 'groupId': 'OG002'}]}]}, {'title': 'Change at C5D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.23', 'spread': '2.348', 'groupId': 'OG000'}, {'value': '-1.03', 'spread': '2.807', 'groupId': 'OG001'}, {'value': '-2.44', 'spread': '2.620', 'groupId': 'OG002'}]}]}, {'title': 'Change at C7D1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.84', 'spread': '2.836', 'groupId': 'OG000'}, {'value': '1.03', 'spread': '2.420', 'groupId': 'OG001'}, {'value': '-2.57', 'spread': '3.695', 'groupId': 'OG002'}]}]}, {'title': 'Change at Follow up', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.54', 'spread': '3.757', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '3.012', 'groupId': 'OG001'}, {'value': '-3.55', 'spread': '5.018', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 of Cycle 3, 5, 7 and safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest [maximum treatment exposure for Phase II was 88 weeks; maximum follow up to 92 weeks])', 'description': 'Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1)', 'unitOfMeasure': 'Kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. All participants reported under "Number of Participants Analyzed" contributed data to the table; however, may not have evaluable data for every row. Here, "Number Analyzed" signifies number of participants evaluable at specified time points.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Overall ECG Abnormalities: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'Standard 12- lead ECGs, average of triplicate assessments was obtained in participant in supine position and within 10 minutes total time. ECG abnormalities included: PR interval (msec): \\>= 220 and change from baseline \\>=20; QRS interval (msec) value \\>=120; uncorrected QT interval, QT correct by QTcB interval and QT correct by QTcF interval (msec): value \\> 450, value \\> 480, value \\> 500, change from baseline \\> 30 and \\> 60. Baseline was defined as the last assessment prior to the date or time of the first dose of study treatment. In this outcome measure number of participants with overall ECG abnormalities are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Hematology Parameters: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Shift from baseline Grade to post-baseline Grade 3: Leukocytes (10^9/L) white blood cells decreased', 'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: Leukocytes (10^9/L) white blood cells decreased', 'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Neutrophils (10^9/L) decreased', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: Neutrophils (10^9/L) decreased', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Platelets (10^9/L) decreased', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 4: Platelets (10^9/L) decreased', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'The following hematology laboratory parameters were assessed: hemoglobin, hematocrit, platelets, WBC, neutrophils, lymphocytes, eosinophils, basophils, monocytes, WBC with automated 5-part differential, RBC, absolute reticulocytes, reticulocytes %, MCH, MCV and RDW. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Baseline was defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants who had hematology parameter abnormality Grade \\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Chemistry Parameters: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Shift from baseline Grade to post-baseline Grade 3: ALT (U/L) increased', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Albumin; Hypoalbuminemia (g/L)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Blood Bilirubin increased (umol/L)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Shift from baseline Grade to post-baseline Grade 3: Magnesium; Hypermagnesemia (mmol/L)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'The following chemistry parameters were assessed: glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate, blood urea nitrogen or urea, creatinine, total protein, albumin, alkaline phosphatase, AST, ALT, total bilirubin, indirect bilirubin, uric acid, calcium, magnesium and LDH. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death related to adverse event. Baseline was defined as last assessment prior to date/time of first dose of study treatment. Number of participants who had chemistry parameter abnormality Grade\\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Dose Modifications: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Participants with dose reduction- Ontorpacept', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '17', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose omitted- Ontorpacept', 'categories': [{'measurements': [{'value': '14', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}]}, {'title': 'Participants with infusion interruption- Ontorpacept', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}]}, {'title': 'Participants with cycle delayed- Ontorpacept', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose reduction- Doxorubicin', 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}]}]}, {'title': 'Participants with dose omitted- Doxorubicin', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Participants with infusion interruption- Doxorubicin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with cycle delayed- Doxorubicin', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 88 weeks for ontorpacept and 25 weeks for doxorubicin)', 'description': 'Dose modifications included dose reduction, dose omitted, infusion interruption and cycle delayed.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Discontinuations: Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'title': 'Ontorpacept', 'categories': [{'measurements': [{'value': '32', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}]}, {'title': 'Doxorubicin', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 88 weeks for ontorpacept and 25 weeks for doxorubicin)', 'description': 'Number of participants with treatment discontinuations during the study treatment were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Progression Free Survival (PFS): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.9', 'comment': 'Upper limit of 95% confidence interval (CI) could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': 'NA'}, {'value': '6.4', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG001', 'lowerLimit': '1.3', 'upperLimit': 'NA'}, {'value': '7.6', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG002', 'lowerLimit': '1.3', 'upperLimit': 'NA'}, {'value': '6.0', 'groupId': 'OG003', 'lowerLimit': '4.1', 'upperLimit': '6.7'}, {'value': '4.3', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG004', 'lowerLimit': '1.6', 'upperLimit': 'NA'}, {'value': '5.6', 'groupId': 'OG005', 'lowerLimit': '3.0', 'upperLimit': '9.7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'PFS was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause, whichever occurred first. PD was defined at least 20% increase in sum of longest diameter (LD) of target lesion, taking reference of smallest sum on study. Participants without PD or death or participants with an event after 2 or more missing/inadequate disease assessment or participants with an event after the start date of alternate anticancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy, whichever is earlier. Kaplan-Meier method was used for analysis.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Overall Survival (OS): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG000', 'lowerLimit': '26.0', 'upperLimit': 'NA'}, {'value': '8.2', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG001', 'lowerLimit': '7.2', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG002', 'lowerLimit': '4.1', 'upperLimit': 'NA'}, {'value': '20.5', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG003', 'lowerLimit': '15.7', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG004', 'lowerLimit': '4.9', 'upperLimit': 'NA'}, {'value': '14.4', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG005', 'lowerLimit': '12.4', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'From the first ontorpacept infusion (Day 1 of Cycle 1) to death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'OS was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to death of any cause. Participants last known to be alive were censored at their last known alive date. Kaplan-Meier method was used for analysis.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Disease Control Rate (DCR): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '66.7', 'groupId': 'OG000', 'lowerLimit': '9.4', 'upperLimit': '99.2'}, {'value': '66.7', 'groupId': 'OG001', 'lowerLimit': '9.4', 'upperLimit': '99.2'}, {'value': '66.7', 'groupId': 'OG002', 'lowerLimit': '9.4', 'upperLimit': '99.2'}, {'value': '75.0', 'groupId': 'OG003', 'lowerLimit': '56.6', 'upperLimit': '88.5'}, {'value': '84.6', 'groupId': 'OG004', 'lowerLimit': '54.6', 'upperLimit': '98.1'}, {'value': '72.7', 'groupId': 'OG005', 'lowerLimit': '49.8', 'upperLimit': '89.3'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From the first dose of study treatment until PD or death, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DCR was defined as the percentage of participants who have achieved CR, PR, or SD lasting at least 4 weeks as per RECIST v1.1 CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. PR: at least 30% decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started. PD: at least 20% increase in sum of longest diameter of target lesions, taking as reference of the smallest sum on study.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Duration of Response (DOR): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.7', 'comment': 'Full range of 95% CI could not be calculated as only one participant was evaluable.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '4.7', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG003', 'lowerLimit': '3.5', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and full range of 95% CI could not be calculated as participant did not have event of interest.', 'groupId': 'OG005', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Time from date of first documented response (CR or PR) to date of documented progression or death of any cause after achieving response or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DOR was defined as time from date of first documented response (CR or PR) to date of documented progression or death of any cause after achieving response. DOR was calculated for participants who achieved CR or PR. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. PR: at least 30% decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. Participants without PD or death or participants with an event after 2 or more missing/inadequate disease assessment or participants with an event after the start date of alternate anticancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy, whichever is earlier.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants who had CR or PR.'}, {'type': 'SECONDARY', 'title': 'Duration of Disease Control (DDC): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}, {'value': '16', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '12.4', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG001', 'lowerLimit': '6.4', 'upperLimit': 'NA'}, {'value': '10.6', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG002', 'lowerLimit': '7.6', 'upperLimit': 'NA'}, {'value': '6.1', 'groupId': 'OG003', 'lowerLimit': '5.9', 'upperLimit': '9.7'}, {'value': '4.7', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG004', 'lowerLimit': '2.1', 'upperLimit': 'NA'}, {'value': '6.1', 'groupId': 'OG005', 'lowerLimit': '4.1', 'upperLimit': '11.8'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Time from first ontorpacept infusion (Day 1 of Cycle 1) to date of documented progression/death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DDC: participants who achieved BOR of SD, as time from first ontorpacept infusion (Day1 of Cycle1) to date of documented PD/death of any cause. Calculated for participants who achieved CR,PR/SD lasting at least 4weeks. CR:disappearance of all target lesion. Any pathological lymph nodes must have reduction in short axis to\\<10 mm. PR:at least 30%decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started. PD:at least 20% increase in sum of LD of target lesion, taking reference of smallest sum on study. Participants without PD/death/with an event after 2/more missing/inadequate disease assessment/with event after start date of alternate anticancer therapy were censored at last response assessment date/last assessment prior to start date of alternate anti-cancer therapy, whichever is earlier.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment. Here "Number of Participants Analyzed" signifies participants evaluable for this outcome measure.'}, {'type': 'SECONDARY', 'title': 'Time to Progression (TTP): Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.9', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG000', 'lowerLimit': '1.2', 'upperLimit': 'NA'}, {'value': '6.4', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG001', 'lowerLimit': '1.3', 'upperLimit': 'NA'}, {'value': '7.6', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG002', 'lowerLimit': '1.3', 'upperLimit': 'NA'}, {'value': '6.0', 'groupId': 'OG003', 'lowerLimit': '4.2', 'upperLimit': '6.7'}, {'value': '4.3', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG004', 'lowerLimit': '1.6', 'upperLimit': 'NA'}, {'value': '5.6', 'groupId': 'OG005', 'lowerLimit': '3.0', 'upperLimit': '9.7'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause or censoring, whichever is first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'TTP was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause, whichever is first; provided death was not considered as an event. PD: at least 20% increase in sum of longest diameter of target lesion, taking reference of smallest sum on study. Participants without PD or death or with an event after 2 or more missing or inadequate disease assessment or with event after start date of alternate anticancer therapy were censored at last response assessment date or last assessment prior to start date of alternate anti-cancer therapy, whichever is earlier.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Time to New Metastases: Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG000', 'lowerLimit': '7.9', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and full range of 95% CI could not be calculated as no participant had event.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and full range of 95% CI could not be calculated as no participant had event.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG003', 'lowerLimit': '6.0', 'upperLimit': 'NA'}, {'value': '4.7', 'comment': 'Upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG004', 'lowerLimit': '1.6', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median and upper limit of 95% CI could not be calculated due to insufficient number of participants with events.', 'groupId': 'OG005', 'lowerLimit': '3.9', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) until the appearance of new lesion or death or censoring date, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'Time to new metastasis was defined as the time from the ontorpacept infusion (Day 1 of Cycle 1) to a new lesion appearance. Participants without new lesion or participants with new metastases after 2 or more missing/inadequate disease assessment or participants with new metastases after the start date of alternate anti-cancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy whichever was earlier.', 'unitOfMeasure': 'Months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With a Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status: Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Baseline up to 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred first (maximum exposure upto 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively)', 'description': 'ECOG performance were classified as 5 grades: 0: fully active, able to carry on all pre-disease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2: ambulatory and capable of all selfcare but unable to carry out any work activities, up and about more than 50% of waking hours; 3: capable of only limited selfcare, confined to bed or chair more than 50% of waking hours and 4: completely disabled, cannot carry on selfcare and totally confined to bed or chair. Higher score indicated lower health status. Worsening of ECOG was defined as a worsening from baseline (i.e., increase) in the ECOG assessment level and was recorded in two consecutive assessments.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With a Worsening of Global Health Status / Quality of Life (QoL) Status: Phase I and Phase II', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'OG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '17', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}, {'value': '12', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Baseline up to 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred first (maximum exposure upto 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively)', 'description': 'QOL was assessed with European organisation for research and treatment of cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30) tool. The EORTC QLQ-C30 is self-administered, self-reported general cancer-specific questionnaire consisting of 30 items covered by one of 3 dimensions: global health status (2 items): functional scales(15 total items addressing either physical, emotional, cognitive/social functioning) and symptom scales(13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea/financial impact). Higher score indicated better overall QoL. Worsening of Global Health Status /QoL assessments was defined as at least a 10-point decrease from baseline in the standardized score (linear transformation) of Global Health Status/QoL.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The FAS included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 milligram per kilogram (mg/kg) as Intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 milligram per meter square (mg/m\\^2) was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'FG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'FG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'FG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'FG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'FG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}], 'periods': [{'title': 'Phase I', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Study terminated by sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}, {'title': 'Phase II', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '32'}, {'groupId': 'FG004', 'numSubjects': '13'}, {'groupId': 'FG005', 'numSubjects': '22'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '32'}, {'groupId': 'FG004', 'numSubjects': '13'}, {'groupId': 'FG005', 'numSubjects': '22'}]}], 'dropWithdraws': [{'type': 'Study terminated by sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '20'}, {'groupId': 'FG004', 'numSubjects': '10'}, {'groupId': 'FG005', 'numSubjects': '10'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '12'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '9'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'The study consisted of two phases: Phase I (dose escalation) and Phase II (dose expansion). Phase I enrolled participants with high-grade leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, angiosarcoma and epithelioid sarcoma. Phase II enrolled participants with high-grade leiomyosarcoma. Participants were treated with ontorpacept (TTI-621) in combination with doxorubicin for the first 6 cycles and ontorpacept alone thereafter.', 'preAssignmentDetails': 'A total of 76 participants were enrolled and treated in the study (Phase I: 9 participants and Phase II: 67 participants).'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '32', 'groupId': 'BG003'}, {'value': '13', 'groupId': 'BG004'}, {'value': '22', 'groupId': 'BG005'}, {'value': '76', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'Phase I: Ontorpacept 0.2 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG001', 'title': 'Phase I: Ontorpacept 0.7 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 0.7 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.7 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG002', 'title': 'Phase I: Ontorpacept 2.0 mg/kg + Doxorubicin', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG003', 'title': 'Phase II: Ontorpacept 0.2 mg/kg + Doxorubicin (Cohort A)', 'description': 'Participants received ontorpacept, 0.2 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 0.2 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG004', 'title': 'Phase II: Ontorpacept 1.0 mg/kg + Doxorubicin (Cohort C)', 'description': 'Participants received ontorpacept, 1.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 1.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG005', 'title': 'Phase II: Ontorpacept 2.0 mg/kg + Doxorubicin (Cohort B)', 'description': 'Participants received ontorpacept, 2.0 mg/kg as IV infusion on Days 1 and 8 of each 21-day cycle up to Cycle 6. Doxorubicin 75 mg/m\\^2 was administered as IV infusion on Day 1 of 21-day cycles for a maximum of 6 cycles. After Cycle 6, participants continued treatment with ontorpacept 2.0 mg/kg as IV infusion on Days 1 and 15 as monotherapy in 28-day cycles until documentation of disease progression or development of unacceptable toxicity and a long-term follow-up period for assessment of overall survival.'}, {'id': 'BG006', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'title': 'Less than (<) 40 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}]}, {'title': '40 - <65 years', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '25', 'groupId': 'BG003'}, {'value': '7', 'groupId': 'BG004'}, {'value': '12', 'groupId': 'BG005'}, {'value': '49', 'groupId': 'BG006'}]}, {'title': '65 - <75 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}, {'value': '18', 'groupId': 'BG006'}]}, {'title': '75 - <85 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '23', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}, {'value': '16', 'groupId': 'BG005'}, {'value': '55', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '21', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '9', 'groupId': 'BG006'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '29', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}, {'value': '19', 'groupId': 'BG005'}, {'value': '64', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}, {'title': 'White', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '24', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}, {'value': '22', 'groupId': 'BG005'}, {'value': '64', 'groupId': 'BG006'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The full analysis set (FAS) included all participants who were enrolled, allocated to treatment, and received at least one non-zero dose of study treatment.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-06-17', 'size': 7734203, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-11-14T14:58', 'hasProtocol': True}, {'date': '2023-11-08', 'size': 524414, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-11-14T14:58', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 76}}, 'statusModule': {'whyStopped': 'Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2021-06-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-11', 'completionDateStruct': {'date': '2023-12-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-14', 'studyFirstSubmitDate': '2021-08-02', 'resultsFirstSubmitDate': '2024-11-14', 'studyFirstSubmitQcDate': '2021-08-02', 'lastUpdatePostDateStruct': {'date': '2024-12-11', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-11-14', 'studyFirstPostDateStruct': {'date': '2021-08-09', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-12-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs: Phase I', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'An adverse event (AE) was any untoward medical occurrence or worsening of a pre-existing medical condition following or during exposure to pharmaceutical product, whether or not considered causally related to product. A serious adverse event (SAE) was an adverse event occurred during any study at any dose of the investigational products that fulfils one or more of following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. TEAEs were those events with onset date occurred during on-treatment period. AEs included SAEs and all Non-SAEs. On-treatment period was defined as time from first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer therapy). Participant with at least one TEAE and one serious TEAEs are reported in this outcome measure.'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 1 (C1D1): Phase I', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 1', 'description': 'Blood pressure included diastolic blood pressure (DBP) and systolic blood pressure (SBP). Mean change from baseline to 30 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D1: Phase I', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 1 Day 8 (C1D8): Phase I', 'timeFrame': 'Baseline, 30 minutes post dose on Day 8 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C1D8: Phase I', 'timeFrame': 'Baseline, 60 minutes post dose on Day 8 of Cycle 1', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C1D8 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 2 Day 1 (C2D1): Phase I', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 2', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C2D1: Phase I', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 2', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C2D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 30 Minutes Post Dose on Cycle 3 Day 1 (C3D1): Phase I', 'timeFrame': 'Baseline, 30 minutes post dose on Day 1 of Cycle 3', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 30 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at 60 Minutes Post Dose on C3D1: Phase I', 'timeFrame': 'Baseline, 60 minutes post dose on Day 1 of Cycle 3', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to 60 minutes post-dose on C3D1 were reported in this outcome measure. Baseline was defined as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Blood Pressure at Safety Follow up: Phase I', 'timeFrame': 'Baseline, Safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to safety follow up visit were reported in this outcome measure. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Body Weight at C3D1: Phase I', 'timeFrame': 'Baseline, Day 1 of Cycle 3', 'description': 'Body weight was measured in kilograms (kg). Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Body Weight at Cycle 5 Day 1 (C5D1): Phase I', 'timeFrame': 'Baseline, Day 1 of Cycle 5', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Body Weight at Cycle 7 Day 1 (C7D1): Phase I', 'timeFrame': 'Baseline, Day 1 of Cycle 7', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Body Weight at Safety Follow up: Phase I', 'timeFrame': 'Baseline, Safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'Body weight was measured in kilograms. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Number of Participants With Overall Electrocardiogram (ECG) Abnormalities: Phase I', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': "Standard 12- lead ECGs, average of triplicate assessments were obtained in participant in supine position and within 10 minutes total time. ECG abnormalities included: PR interval (millisecond \\[msec\\]): value greater than or equal to (\\>=) 220 and change from baseline \\>=20; QRS interval (msec) value \\>=120; uncorrected QT interval, QT correct by Bazzette's formula (QTcB) interval and QT correct by Frederica formula (QTcF) interval (msec): value greater than (\\>) 450, value \\> 480, value \\> 500, change from baseline \\> 30 and \\> 60. Baseline was defined as the last assessment prior to the date or time of the first dose of study treatment. In this outcome measure number of participants with overall ECG abnormalities are reported."}, {'measure': 'Number of Participants With Shift in National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v)5.0 Grade <=2 at Baseline to >=3 Post-baseline in Hematology Parameters: Phase I', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'The following hematology laboratory parameters were assessed: hemoglobin, hematocrit, platelets, white blood cells (WBC), neutrophils, lymphocytes, eosinophils, basophils, monocytes, WBC with automated 5-part differential, Red blood cells (RBC), absolute reticulocytes, reticulocytes percentage (%), Mean corpuscular hemoglobin (MCH), Mean corpuscular volume (MCV) and Red cell distribution width (RDW). Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Baseline was defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants who had hematology parameter abnormality Grade \\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.'}, {'measure': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Chemistry Parameters: Phase I', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase I was 74.1 weeks; maximum follow up to approx. 78.1 weeks)', 'description': 'The following chemistry parameters were assessed: glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate, blood urea nitrogen or urea, creatinine, total protein, albumin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, indirect bilirubin, uric acid, calcium, magnesium, lactate dehydrogenase (LDH). Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death related to adverse event. Baseline was defined as last assessment prior to date/time of first dose of study treatment. Number of participants who had chemistry parameter abnormality Grade\\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.'}, {'measure': 'Number of Participants With Dose Modifications: Phase I', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 74.1 weeks for ontorpacept and 20.1 weeks for doxorubicin)', 'description': 'Dose modifications included dose reduction, dose omitted, infusion interruption and cycle delayed.'}, {'measure': 'Number of Participants With Treatment Discontinuations: Phase I', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 74.1 weeks for ontorpacept and 20.1 weeks for doxorubicin)', 'description': 'Number of participants with treatment discontinuations during the study treatment were reported in this outcome measure.'}, {'measure': 'Objective Response Rate (ORR): Phase I and Phase II', 'timeFrame': 'From the start of study treatment until disease progression (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': "ORR: percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) based on investigator's assessment per response evaluation criteria in solid tumours RECIST version (v)1.1. BOR: best response recorded from start of treatment until disease progression (PD). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than(\\< )10 mm. PR: at least 30 percent (%) decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. PD: at least 20% increase in sum of longest diameter of target lesions, taking as reference of the smallest sum on study."}], 'secondaryOutcomes': [{'measure': 'Number of Participants With TEAEs and Serious TEAEs: Phase II', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'An AE was any untoward medical occurrence or worsening of a pre-existing medical condition following or during exposure to pharmaceutical product, whether or not considered causally related to product. A SAE was an adverse event occurred during any study at any dose of the investigational products that fulfils one or more of following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. TEAEs were those events with onset date occurred during on-treatment period. AEs included SAEs and all Non-SAEs. On-treatment period was defined as time from first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer therapy). Participant with at least one TEAE and one serious TEAEs are reported in this outcome measure.'}, {'measure': 'Mean Change From Baseline in Blood Pressure: Phase II', 'timeFrame': 'Baseline, 30 and 60min post dose of C1D1,C1D8,C2D1,C3D1 and safety follow up 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure of Phase II:88 weeks;maximum follow up:92 weeks)', 'description': 'Blood pressure included DBP and SBP. Mean change from baseline to safety follow up visit were reported in this outcome measure. Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1).'}, {'measure': 'Mean Change From Baseline in Body Weight: Phase II', 'timeFrame': 'Baseline, Day 1 of Cycle 3, 5, 7 and safety follow up (up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest [maximum treatment exposure for Phase II was 88 weeks; maximum follow up to 92 weeks])', 'description': 'Baseline was considered as the last measurement taken prior to the first infusion of study medication (Day 1 of Cycle 1)'}, {'measure': 'Number of Participants With Overall ECG Abnormalities: Phase II', 'timeFrame': 'From first dose of study treatment (Day 1) up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'Standard 12- lead ECGs, average of triplicate assessments was obtained in participant in supine position and within 10 minutes total time. ECG abnormalities included: PR interval (msec): \\>= 220 and change from baseline \\>=20; QRS interval (msec) value \\>=120; uncorrected QT interval, QT correct by QTcB interval and QT correct by QTcF interval (msec): value \\> 450, value \\> 480, value \\> 500, change from baseline \\> 30 and \\> 60. Baseline was defined as the last assessment prior to the date or time of the first dose of study treatment. In this outcome measure number of participants with overall ECG abnormalities are reported.'}, {'measure': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Hematology Parameters: Phase II', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'The following hematology laboratory parameters were assessed: hemoglobin, hematocrit, platelets, WBC, neutrophils, lymphocytes, eosinophils, basophils, monocytes, WBC with automated 5-part differential, RBC, absolute reticulocytes, reticulocytes %, MCH, MCV and RDW. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Baseline was defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants who had hematology parameter abnormality Grade \\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.'}, {'measure': 'Number of Participants With Shift in NCI-CTCAE v5.0 Grade <=2 at Baseline to >=3 Post-baseline in Chemistry Parameters: Phase II', 'timeFrame': 'Baseline up to 30 Days post last dose of study treatment or start of new anti-cancer therapy whichever occurred soonest (maximum treatment exposure for Phase II was 88 weeks; maximum follow up to approx. 92 weeks)', 'description': 'The following chemistry parameters were assessed: glucose, sodium, potassium, calcium, chloride, phosphate, bicarbonate, blood urea nitrogen or urea, creatinine, total protein, albumin, alkaline phosphatase, AST, ALT, total bilirubin, indirect bilirubin, uric acid, calcium, magnesium and LDH. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death related to adverse event. Baseline was defined as last assessment prior to date/time of first dose of study treatment. Number of participants who had chemistry parameter abnormality Grade\\<=2 at baseline and shifted to \\>=3 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.'}, {'measure': 'Number of Participants With Dose Modifications: Phase II', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 88 weeks for ontorpacept and 25 weeks for doxorubicin)', 'description': 'Dose modifications included dose reduction, dose omitted, infusion interruption and cycle delayed.'}, {'measure': 'Number of Participants With Treatment Discontinuations: Phase II', 'timeFrame': 'During study treatment (from first dose of study treatment [Day 1] to maximum treatment exposure of 88 weeks for ontorpacept and 25 weeks for doxorubicin)', 'description': 'Number of participants with treatment discontinuations during the study treatment were reported in this outcome measure.'}, {'measure': 'Progression Free Survival (PFS): Phase I and Phase II', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'PFS was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause, whichever occurred first. PD was defined at least 20% increase in sum of longest diameter (LD) of target lesion, taking reference of smallest sum on study. Participants without PD or death or participants with an event after 2 or more missing/inadequate disease assessment or participants with an event after the start date of alternate anticancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy, whichever is earlier. Kaplan-Meier method was used for analysis.'}, {'measure': 'Overall Survival (OS): Phase I and Phase II', 'timeFrame': 'From the first ontorpacept infusion (Day 1 of Cycle 1) to death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'OS was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to death of any cause. Participants last known to be alive were censored at their last known alive date. Kaplan-Meier method was used for analysis.'}, {'measure': 'Disease Control Rate (DCR): Phase I and Phase II', 'timeFrame': 'From the first dose of study treatment until PD or death, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DCR was defined as the percentage of participants who have achieved CR, PR, or SD lasting at least 4 weeks as per RECIST v1.1 CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. PR: at least 30% decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started. PD: at least 20% increase in sum of longest diameter of target lesions, taking as reference of the smallest sum on study.'}, {'measure': 'Duration of Response (DOR): Phase I and Phase II', 'timeFrame': 'Time from date of first documented response (CR or PR) to date of documented progression or death of any cause after achieving response or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DOR was defined as time from date of first documented response (CR or PR) to date of documented progression or death of any cause after achieving response. DOR was calculated for participants who achieved CR or PR. CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \\<10 mm. PR: at least 30% decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. Participants without PD or death or participants with an event after 2 or more missing/inadequate disease assessment or participants with an event after the start date of alternate anticancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy, whichever is earlier.'}, {'measure': 'Duration of Disease Control (DDC): Phase I and Phase II', 'timeFrame': 'Time from first ontorpacept infusion (Day 1 of Cycle 1) to date of documented progression/death of any cause or censoring, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'DDC: participants who achieved BOR of SD, as time from first ontorpacept infusion (Day1 of Cycle1) to date of documented PD/death of any cause. Calculated for participants who achieved CR,PR/SD lasting at least 4weeks. CR:disappearance of all target lesion. Any pathological lymph nodes must have reduction in short axis to\\<10 mm. PR:at least 30%decrease in sum of longest diameter of target lesions, taking as reference baseline sum longest diameter. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum LD since treatment started. PD:at least 20% increase in sum of LD of target lesion, taking reference of smallest sum on study. Participants without PD/death/with an event after 2/more missing/inadequate disease assessment/with event after start date of alternate anticancer therapy were censored at last response assessment date/last assessment prior to start date of alternate anti-cancer therapy, whichever is earlier.'}, {'measure': 'Time to Progression (TTP): Phase I and Phase II', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause or censoring, whichever is first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'TTP was defined as the time from the first ontorpacept infusion (Day 1 of Cycle 1) to PD or death of any cause, whichever is first; provided death was not considered as an event. PD: at least 20% increase in sum of longest diameter of target lesion, taking reference of smallest sum on study. Participants without PD or death or with an event after 2 or more missing or inadequate disease assessment or with event after start date of alternate anticancer therapy were censored at last response assessment date or last assessment prior to start date of alternate anti-cancer therapy, whichever is earlier.'}, {'measure': 'Time to New Metastases: Phase I and Phase II', 'timeFrame': 'Time from the first ontorpacept infusion (Day 1 of Cycle 1) until the appearance of new lesion or death or censoring date, whichever occurred first (maximum exposure up to 74.1 weeks for Phase I and 88 weeks for Phase II)', 'description': 'Time to new metastasis was defined as the time from the ontorpacept infusion (Day 1 of Cycle 1) to a new lesion appearance. Participants without new lesion or participants with new metastases after 2 or more missing/inadequate disease assessment or participants with new metastases after the start date of alternate anti-cancer therapy were censored at their last response assessment date or last assessment prior to the start date of alternate anti-cancer therapy whichever was earlier.'}, {'measure': 'Number of Participants With a Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status: Phase I and Phase II', 'timeFrame': 'From Baseline up to 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred first (maximum exposure upto 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively)', 'description': 'ECOG performance were classified as 5 grades: 0: fully active, able to carry on all pre-disease performance without restriction; 1: restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2: ambulatory and capable of all selfcare but unable to carry out any work activities, up and about more than 50% of waking hours; 3: capable of only limited selfcare, confined to bed or chair more than 50% of waking hours and 4: completely disabled, cannot carry on selfcare and totally confined to bed or chair. Higher score indicated lower health status. Worsening of ECOG was defined as a worsening from baseline (i.e., increase) in the ECOG assessment level and was recorded in two consecutive assessments.'}, {'measure': 'Number of Participants With a Worsening of Global Health Status / Quality of Life (QoL) Status: Phase I and Phase II', 'timeFrame': 'From Baseline up to 30 Days post last dose of study treatment/start of new anti-cancer therapy whichever occurred first (maximum exposure upto 74.1 and 88 weeks; maximum follow up to approx. 78.1 and 92 weeks for Phase I and II respectively)', 'description': 'QOL was assessed with European organisation for research and treatment of cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30) tool. The EORTC QLQ-C30 is self-administered, self-reported general cancer-specific questionnaire consisting of 30 items covered by one of 3 dimensions: global health status (2 items): functional scales(15 total items addressing either physical, emotional, cognitive/social functioning) and symptom scales(13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea/financial impact). Higher score indicated better overall QoL. Worsening of Global Health Status /QoL assessments was defined as at least a 10-point decrease from baseline in the standardized score (linear transformation) of Global Health Status/QoL.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Leiomyosarcoma', 'Pleomorphic sarcoma', 'Myxofibrosarcoma', 'Liposarcoma', 'Angiosarcoma', 'Epithelioid sarcoma'], 'conditions': ['Leiomyosarcoma']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=TTI-621-03', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with leiomyosarcoma. Leiomyosarcoma is a tumor of the smooth muscles.\n\nThis study is seeking participants who have:\n\n* leiomyosarcoma that is advanced or has spread to other parts of the body (metastatic)\n* not received prior treatment with anthracyclines (a drug commonly used in patients with some kinds of cancer, including leiomyosarcoma)\n* not received more than one prior treatment for their leiomyosarcoma During the first 18 weeks of this study, participants will receive doxorubicin by IV infusion (given directly into a vein) at the study clinic every 3 weeks for a total of 6 doses. Participants will also receive Ontorpacept (TTI-621) by IV infusion at the study clinic on the same day as doxorubicin and again one week later for the first 18 weeks.\n\nAfter the first 18 weeks, participants will stop receiving doxorubicin but will continue receiving Ontorpacept (TTI-621) as IV infusion every 14 days at the study clinic. They will keep receiving Ontorpacept (TTI-621) until their cancer is no longer responding to treatment.\n\nWe will examine the experiences of participants receiving Ontorpacept (TTI-621) in combination with doxorubicin in the first 18 weeks and then Ontorpacept (TTI-621) by itself after the doxorubicin is stopped. This will help us determine if the study medicine Ontorpacept (TTI-621) given with doxorubicin and then by itself is safe and effective.\n\nParticipants will be involved in the study for approximately one year, depending on how their cancer responds to the study treatment. They will have study visits about 12 times in the first 18 weeks (when the study medicine Ontorpacept is given with doxorubicin) and then every two weeks after the doxorubicin is stopped and the study medicine Ontorpacept (TTI-621) is given by itself.', 'detailedDescription': 'This trial will be conducted in 2 phases: Phase I (dose escalation of Ontorpacept in combination with fixed-dose doxorubicin) and Phase II (dose expansion of Ontorpacept in combination with fixed-dose doxorubicin).\n\nPhase I will enroll patients with soft-tissue sarcomas including leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, angiosarcoma or epithelioid sarcoma to evaluate escalating doses of Ontorpacept (TTI-621) administered in combination with fixed-dose doxorubicin for up to six cycles followed by Ontorpacept (TTI-621) monotherapy.\n\nPhase II will enroll patients with high-grade leiomyosarcoma and will evaluate two dose levels of Ontorpacept (TTI-621) in combination with fixed-dose doxorubicin for up to six cycles followed by Ontorpacept (TTI-621) monotherapy.\n\n.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria:\n\n1. Eastern Co-operative Oncology Group Performance Status Performance Status (ECOG-PS) 0 or 1.\n2. Histologically-confirmed high-grade soft tissue sarcoma that is metastatic or locally advanced and not amenable to curative treatment with surgery or radiation.\n\n 1. In the Dose Escalation phase, indications will be limited to high-grade leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, angiosarcoma and epithelioid sarcoma\n 2. In the Dose Expansion phase, indications will be limited to high-grade leiomyosarcoma.\n3. Objective evidence of disease progression unless disease is newly-diagnosed.\n4. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (expansion cohorts).\n5. Adequate organ and hematologic function.\n6. No more than 1 prior treatment regimen for advanced disease, which is limited to gemcitabine with docetaxel.\n7. Anthracycline-naïve.\n8. Patients who were treated with a prior chemotherapy regimen must have completed treatment at least three weeks before initiation of study treatment.\n9. All adverse events from prior treatment must be NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v5 Grade ≤ 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline.\n10. Radiotherapy, including palliative radiotherapy, completed at least two weeks prior to treatment; palliative radiation to non-target lesions while on study is allowed.\n\nKey Exclusion Criteria:\n\n1. History of acute coronary syndromes.\n2. History of or current Class II, III, or IV heart failure.\n3. History or evidence of known CNS (central nervous system) metastases or carcinomatous meningitis.\n4. Significant bleeding disorders, vasculitis or a significant bleeding episode from the GI (gastrointestinal) tract.\n5. History of severe hypersensitivity reactions to antibodies.\n6. Systemic steroid therapy.\n7. History or autoimmune disease that has required systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs.\n8. Prior organ transplantation including allogenic or autologous stem cell transplantation\n9. Prior treatment with anti-CD47 (Cluster of Differentiation 47) or anti-signal regulatory protein alpha (SIRPα) therapy.'}, 'identificationModule': {'nctId': 'NCT04996004', 'acronym': 'TTI-621-03', 'briefTitle': 'A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase I/II Study of TTI-621 in Combination With Doxorubicin in Patients With Unresectable or Metastatic High-Grade Leiomyosarcoma', 'orgStudyIdInfo': {'id': 'TTI-621-03'}, 'secondaryIdInfos': [{'id': 'C4961003', 'type': 'OTHER', 'domain': 'Alias Study Number'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dose Escalation (Ontorpacept+doxorubicin)', 'description': 'In the dose escalation portion of the study, participants with specific subsets of soft tissue sarcomas who have not received more than one prior line of therapy and have not received an anthracycline in any setting will be enrolled in three escalating dose cohorts to characterize the safety and tolerability of Ontorpacept (TTI-621) when administered in combination with doxorubicin for up to six cycles and followed by Ontorpacept (TTI-621) monotherapy', 'interventionNames': ['Drug: Ontorpacept (TTI-621)', 'Drug: Doxorubicin']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion Dose Level A (Cohort A)', 'description': 'Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level A) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.', 'interventionNames': ['Drug: Ontorpacept (TTI-621)', 'Drug: Doxorubicin']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion Dose Level B (Cohort B)', 'description': 'Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level B) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.', 'interventionNames': ['Drug: Ontorpacept (TTI-621)', 'Drug: Doxorubicin']}, {'type': 'EXPERIMENTAL', 'label': 'Dose Expansion Dose Level C (Cohort C)', 'description': 'Participants with high-grade leiomyosarcoma will receive up to six cycles of Ontorpacept (TTI-621) at a pre-specified dose level (Dose Level C) in combination with fixed-dose doxorubicin followed by Ontorpacept (TTI-621) monotherapy to further characterize safety, tolerability, and clinical activity of the treatment regimen.', 'interventionNames': ['Drug: Ontorpacept (TTI-621)', 'Drug: Doxorubicin']}], 'interventions': [{'name': 'Ontorpacept (TTI-621)', 'type': 'DRUG', 'otherNames': ['Ontorpacept / SIRPα-IgG1 Fc'], 'description': 'Ontorpacept (TTI-621) will be administered by intravenous infusion.', 'armGroupLabels': ['Dose Escalation (Ontorpacept+doxorubicin)', 'Dose Expansion Dose Level A (Cohort A)', 'Dose Expansion Dose Level B (Cohort B)', 'Dose Expansion Dose Level C (Cohort C)']}, {'name': 'Doxorubicin', 'type': 'DRUG', 'otherNames': ['Adriamycin'], 'description': '75 mg/m\\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.', 'armGroupLabels': ['Dose Escalation (Ontorpacept+doxorubicin)', 'Dose Expansion Dose Level A (Cohort A)', 'Dose Expansion Dose Level B (Cohort B)', 'Dose Expansion Dose Level C (Cohort C)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90403', 'city': 'Santa Monica', 'state': 'California', 'country': 'United States', 'facility': 'Sarcoma Oncology Research Center', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic Florida', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Moffitt Cancer Center', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'University of Iowa Hospital and Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '07920', 'city': 'Basking Ridge', 'state': 'New Jersey', 'country': 'United States', 'facility': 'MSK Basking Ridge.', 'geoPoint': {'lat': 40.70621, 'lon': -74.54932}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Hackensack University Medical Center', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '07748', 'city': 'Middletown', 'state': 'New Jersey', 'country': 'United States', 'facility': 'MSK Monmouth', 'geoPoint': {'lat': 40.39428, 'lon': -74.11709}}, {'zip': '07645', 'city': 'Montvale', 'state': 'New Jersey', 'country': 'United States', 'facility': 'MSK Bergen', 'geoPoint': {'lat': 41.04676, 'lon': -74.02292}}, {'zip': '11725', 'city': 'Commack', 'state': 'New York', 'country': 'United States', 'facility': 'MSK Commack.', 'geoPoint': {'lat': 40.84288, 'lon': -73.29289}}, {'zip': '10604', 'city': 'Harrison', 'state': 'New York', 'country': 'United States', 'facility': 'MSK Westchester', 'geoPoint': {'lat': 40.96899, 'lon': -73.71263}}, {'zip': '11101', 'city': 'Long Island City', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy', 'geoPoint': {'lat': 40.74482, 'lon': -73.94875}}, {'zip': '10022', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center 53rd street.', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center - Main Campus', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Memorial Sloan Kettering Cancer Center 53rd street.', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '11553', 'city': 'Uniondale', 'state': 'New York', 'country': 'United States', 'facility': 'MSK Nassau', 'geoPoint': {'lat': 40.70038, 'lon': -73.59291}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University Hospitals Cleveland Medical Center', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health & Science University (OHSU)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health and Science University - Center for Health and Healing 1 (CHH1)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health and Science University - Center for Health and Healing 2(CHH2)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC Hillman Cancer Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Cancer Specialists', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'zip': '53792', 'city': 'Madison', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'University of Wisconsin Clinical Science Center', 'geoPoint': {'lat': 43.07305, 'lon': -89.40123}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'url': 'https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests', 'ipdSharing': 'YES', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}